Issue link: https://www.e-digitaleditions.com/i/648486
Ropack Pharma Solutions Company manufactures and packages pharmaceuticals from early-stage for- mulation through commercialization. Clinical manufacturing capabilities include blending, compression, granu- lation, coating, and encapsulation. Company also offers R&D, analytics, commercial manufacturing, packaging, and distribution services. FDA-licensed facilities—two in Long Island, NY, and four in Montreal, Canada—comprise more than 450,000 square feet. Packag- ing for nutraceutical products is also available. Ropack Pharma Solutions, Commack, NY. Tel. 631 482 7777 www.ropack.com Ruspak Contract packager ensures project and product confidentiality and on-time delivery for pharmaceuticals and nutraceuticals. Standard packaging includes blisters, bottles, pouches, and strip packs. Packaging of gum tablets into blisters and pouches is also avail- able. Secondary packaging services include shrinkwrapping, labeling, and cartooning. Customers work directly with owner of company, which is reg- istered with FDA, DEA and New York State Board of Pharmacy. It is approved to handle Schedule III and IV con- trolled substances, as well as controlled chemicals on List 1. Ruspak, Lyons, NY. Tel. 315 946 9777 www.ruspak.com Aesica Pharmaceuticals Company develops and manufactures APIs and finished dosage forms. Acquired by Consort Medical in November 2014, company offers to manage other CDMOs and serve as central contact to streamline customer interactions, simplify supply chain, and improve on-time delivery. Company also offers semi-continuous pro- cessing to accelerate drug development, reduce amount of API required, and mini- mize loss from cleaning between batches. Facilities handle APIs up to Safebridge Category III and Schedule II controlled substances. Aesica Pharmaceuticals, Newcastle upon Tyne, UK. Tel. +44 191 218 1960 www.aesica-pharma.com Xcelience Contract research organization offers suite of services from pre-formulation through clinical distribution, including micronization, analytical and method development and validation, formulation development, cGMP manufacturing, small-scale com- mercial manufacturing, and global clinical supplies packaging. Company offers API- sparing strategies, including neat API-in-capsule service that reduces time to first- in-human studies by as much as 45 percent compared to traditional drug development programs. Company was acquired by Capsugel in January. Xcelience, Tampa, FL. Tel. 813 286 0404 www.xcelience.com 18 March 2016 Tablets & Capsules